Jon Gustafson, MD
Neurology · Fort Smith, ARNPI 1275583551
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,090 of the $2,453 with a category attached, or 85.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $604 and has fallen 56.8% since, to $261 in 2025.
Across 102 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$511
- Biogen$455
- Eisai Inc.$302
- Pfizer$272
- UCB, Inc.$252
- Lundbeck LLC$139
- plus $522 from 8 others
Across 9 payments — averaging $1044.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$9K
What the payments were for
- Consulting fees$30012%
- Food & beverage$2,09085%
- Education$633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $511 |
| Biogen | 8 | $455 |
| Eisai Inc. | 4 | $302 |
| Pfizer | 12 | $272 |
| UCB, Inc. | 13 | $252 |
| Lundbeck LLC | 2 | $139 |
| Supernus Pharmaceuticals, Inc. | 8 | $132 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $131 |
| Argenx US, Inc. | 1 | $93 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Genentech USA, Inc. | 2 | $43 |
| Novartis | 2 | $35 |
| EMD Serono, Inc. | 2 | $31 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,453 in reported general payments places this provider in the 55th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 25 | $290,676 |
| Kesimpta PenOfatumumab | 11 | $105,047 |
| QuliptaAtogepant | 25 | $34,158 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $33,156 |
| BriviactBrivaracetam | 24 | $27,546 |
| Nurtec OdtRimegepant Sulfate | 14 | $26,030 |
| Glatiramer Acetate | 15 | $20,799 |
| Keppra XrLevetiracetam | 11 | $17,435 |
| NeuproRotigotine | 16 | $15,999 |
| Tetrabenazine | 11 | $9,736 |
| Oxcarbazepine | 56 | $3,841 |
| Lacosamide | 32 | $3,683 |
| Tegretol XrCarbamazepine | 12 | $3,416 |
| Levetiracetam | 99 | $3,352 |
| Gabapentin | 70 | $2,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Neupro | $252 | $43,54540 claims |
| AbbVieQulipta | $511 | $34,15825 claims |
| PfizerNurtec Odt | $272 | $26,03014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 93 neurology providers in Arkansas.
Other neurology in Fort Smith
- Steve-Felix BelingaFort Smith$183K
- William KnubleyFort Smith$26K
- Tonya PhillipsFort Smith$17K
- Janice KeatingFort Smith$16K
- Satish GaddamFort Smith$14K
- Vasile PopaFort Smith$8K
- John KareusFort Smith$3K
- Pradeep KumbhamFort Smith$2K
- Kathryn ChenaultSherwood$532K
- Michael MorseFayetteville$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.